Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan;20(1):30-37.
doi: 10.1513/AnnalsATS.202204-328OC.

Heterogeneity of Lung Function Phenotypes in Sarcoidosis: Role of Race and Sex Differences

Affiliations

Heterogeneity of Lung Function Phenotypes in Sarcoidosis: Role of Race and Sex Differences

Michelle Sharp et al. Ann Am Thorac Soc. 2023 Jan.

Abstract

Rationale: Historically, sarcoidosis was described as a restrictive lung disease, but several alternative phenotypes of pulmonary function have been observed. Pulmonary function phenotypes in sarcoidosis may represent different clinical and/or molecular phenotypes. Objectives: To characterize the prevalence of different pulmonary function phenotypes in a large and diverse sarcoidosis cohort from a tertiary care referral center. Methods: We identified individuals seen between 2005-2015 with a confirmed diagnosis of sarcoidosis. Data were collected from the first pulmonary function test (PFT) performed at our institution which included spirometry and diffusing capacity of the lung for carbon monoxide (DlCO). Demographics and clinical data were collected. Chi-squared analyses and multiple linear regressions were done to assess statistical differences and associations. Global Lung Function Initiative equations were used to calculate percent predicted measurements for spirometry and DlCO. Results: Of 602 individuals with sarcoidosis, 93% (562) had pulmonary involvement, 64% (385) were female, and 57% (341) were Black. Of those with pulmonary involvement, 56% had abnormal pulmonary function. Lung function impairment phenotypes included: 47% restriction, 22% obstruction, 15% isolated reduction in DlCO, and 16% combined obstructive restrictive phenotype. Restriction was the most common PFT phenotype among Black individuals (41%), while no lung impairment was most common among White individuals (66%) (P < 0.001). Males more frequently had obstruction (19%) compared with females (9%) P = 0.001, and females had more restriction (30%) compared with males (21%) P = 0.031. Conclusions: Among individuals with sarcoidosis and pulmonary function impairment, less than half demonstrated a restrictive phenotype. There were significant differences in pulmonary function phenotypes by race and sex.

Keywords: pulmonary disease; respiratory function tests; sarcoidosis.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Inclusion of participants for analysis.
Figure 2.
Figure 2.
Prevalence of pulmonary function phenotypes by A) Race and B) Sex. Restriction was defined as FVC < the lower limit of normal (LLN) with FEV1/FVC ⩾ (LLN), obstruction as FEV1/FVC ⩽ LLN with FVC ⩾ LLN, combined (obstruction/restriction) as FVC < LLN and FEV1/FVC < LLN, and isolated gas transfer defect as DlCO < LLN with no restrictive or obstructive defect. Normal was defined as not having any impairment. DlCO = diffusing capacity of the lung for carbon monoxide; FEV1 = forced expiratory volume in one second; FVC = forced vital capacity; LLN = lower limit of normal.

Comment in

References

    1. Costabel U, Hunninghake GW, Sarcoidosis Statement Committee. American Thoracic Society. European Respiratory Society. World Association for Sarcoidosis and Other Granulomatous Disorders ATS/ERS/WASOG statement on sarcoidosis. Eur Respir J . 1999;14:735–737. - PubMed
    1. Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H, Jr, Bresnitz EA, et al. Case Control Etiologic Study of Sarcoidosis (ACCESS) research group Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med . 2001;164:1885–1889. - PubMed
    1. Markevitz N, Epstein Shochet G, Levi Y, Israeli-Shani L, Shitrit D. Sarcoidosis in Israel: clinical outcome status, organ involvement, and long-term follow-up. Lung . 2017;195:419–424. - PubMed
    1. Te HS, Perlman DM, Shenoy C, Steinberger DJ, Cogswell RJ, Roukoz H, et al. Clinical characteristics and organ system involvement in sarcoidosis: comparison of the University of Minnesota Cohort with other cohorts. BMC Pulm Med . 2020;20:155. - PMC - PubMed
    1. Baughman RP, Drent M, Kavuru M, Judson MA, Costabel U, du Bois R, et al. Sarcoidosis Investigators Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med . 2006;174:795–802. - PubMed

Publication types